Reported Q: Q2 2025 Rev YoY: +1.0% EPS YoY: +29.8% Move: -4.01%
Maximus Inc
MMS
$75.08 -4.01%
Exchange NYSE Sector Industrials Industry Specialty Business Services
Q2 2025
Published: May 8, 2025

Company Status Snapshot

Fast view of the latest quarter outcome for MMS

Reported

Report Date

May 8, 2025

Quarter Q2 2025

Revenue

1.36B

YoY: +1.0%

EPS

1.69

YoY: +29.8%

Market Move

-4.01%

Previous quarter: Q1 2025

Follow this company to get upcoming quarter alerts automatically.

Earnings Highlights

  • Revenue of $1.36B up 1% year-over-year
  • EPS of $1.69 increased by 29.8% from previous year
  • Gross margin of 24.9%
  • Net income of 96.57M
  • ""investments that we've been focused on in terms of robotic process automation initially, but then into machine learning and now artificial intelligence are really starting to pay off."" - Bruce L. Caswell
MMS
Company MMS

Executive Summary

Maximus delivered a solid Q2 FY2025 with 3% organic revenue growth to $1.36 billion and an adjusted EBITDA margin of 13.7%, landing at the upper end of its near-term guidance. The U.S. Federal Services segment was the primary growth driver, offsetting normalization in U.S. Services post-Medicaid unwinding and contributing to strong overall profitability. The company reinforced its strategic focus on Maximus Forward—leveraging automation, AI, and process improvements to boost productivity and scale across government programs. Management raised full-year revenue guidance by $50 million and nudged up adjusted EBITDA margin guidance by 50 bps, signaling confidence in operating performance despite a cautious outlook for the second half amid government spending scrutiny. The pipeline remains robust (41.2B total; 2.9B awarded; 451M awarded but not signed), underpinning a favorable medium-term growth trajectory, though near-term cash flow was pressured by higher DSO driven by state program extensions. In sum, Maximus exhibits meaningful margin expansion in core federal work, a diversified portfolio with continued growth potential in international and clinical assessment services, and a disciplined capital allocation strategy that includes opportunistic buybacks and selective M&A considerations.

Key Performance Indicators

Revenue
Increasing
1.36B
QoQ: -2.92% | YoY: 1.00%
Gross Profit
Increasing
338.82M
24.88% margin
QoQ: 12.36% | YoY: 14.49%
Operating Income
Increasing
152.97M
QoQ: 76.26% | YoY: 19.77%
Net Income
Increasing
96.57M
QoQ: 134.41% | YoY: 19.95%
EPS
Increasing
1.70
QoQ: 146.38% | YoY: 29.77%

Revenue Trend

Margin Analysis

Historical Earnings Comparison

PeriodRevenue ($M)EPS ($)YoY GrowthReport
Q2 2025 1,361.79 1.69 +1.0% View
Q1 2025 1,402.68 0.69 +5.7% View
Q4 2024 1,315.87 -3.81 +4.4% View
Q3 2024 1,314.93 1.46 +10.6% View
Q2 2024 1,348.36 1.31 +11.7% View